LLY

824.19

+0.92%↑

JNJ

157.35

+1.12%↑

ABBV

192.45

+0.48%↑

NVO

80.66

+0.47%↑

UNH

316.48

+0.14%↑

LLY

824.19

+0.92%↑

JNJ

157.35

+1.12%↑

ABBV

192.45

+0.48%↑

NVO

80.66

+0.47%↑

UNH

316.48

+0.14%↑

LLY

824.19

+0.92%↑

JNJ

157.35

+1.12%↑

ABBV

192.45

+0.48%↑

NVO

80.66

+0.47%↑

UNH

316.48

+0.14%↑

LLY

824.19

+0.92%↑

JNJ

157.35

+1.12%↑

ABBV

192.45

+0.48%↑

NVO

80.66

+0.47%↑

UNH

316.48

+0.14%↑

LLY

824.19

+0.92%↑

JNJ

157.35

+1.12%↑

ABBV

192.45

+0.48%↑

NVO

80.66

+0.47%↑

UNH

316.48

+0.14%↑

Search

Corvus Pharmaceuticals Inc

Open

4.28 -4.25

Overview

Share price change

24h

Current

Min

4.21

Max

4.53

Key metrics

By Trading Economics

Income

27M

15M

EPS

-0.138

Employees

31

EBITDA

-1.8M

-9.9M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+206.6% upside

Dividends

By Dow Jones

Next Earnings

5 Aug 2025

Market Stats

By TradingEconomics

Market Cap

35M

312M

Previous open

8.53

Previous close

4.28

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

Corvus Pharmaceuticals Inc Chart

Past performance is not a reliable indicator of future results.

Related News

12 Jun 2025, 20:41 UTC

Earnings

Adobe Raises Outlook After 2Q Sales Beat

12 Jun 2025, 23:50 UTC

Earnings

Adobe Keeps Pivoting as AI Transforms Customer Needs -- Update

12 Jun 2025, 23:50 UTC

Earnings

Adobe Customer Demand Shifting Toward Idea Generation, CFO Says

12 Jun 2025, 23:50 UTC

Earnings

Adobe FireFly Products Drove Revenue Beat in 2Q, CFO Says

12 Jun 2025, 23:48 UTC

Market Talk

Gold Steady Amid Geopolitical Risks -- Market Talk

12 Jun 2025, 23:45 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

12 Jun 2025, 23:45 UTC

Market Talk

Nikkei May Trade Rangebound Amid Tariff Uncertainty -- Market Talk

12 Jun 2025, 21:26 UTC

Earnings

Friedman Industries 4Q Sales $129.2M >FRD

12 Jun 2025, 21:25 UTC

Earnings

Friedman Industries 4Q EPS 76c >FRD

12 Jun 2025, 21:11 UTC

Earnings

Adobe Beat Estimates and Raises Revenue Guidance -- Barrons.com

12 Jun 2025, 20:50 UTC

Market Talk
Earnings

Tech, Media & Telecom Roundup: Market Talk

12 Jun 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

12 Jun 2025, 20:31 UTC

Earnings

Adobe Beat Estimates and Raises Revenue Guidance -- Barrons.com

12 Jun 2025, 20:30 UTC

Earnings
Acquisitions, Mergers, Takeovers

Chime IPO: Stock Soars in Nasdaq Debut, Valuing It at Nearly $14 Billion -- Barrons.com

12 Jun 2025, 20:15 UTC

Earnings

Adobe Sees FY25 Rev $23.5B-$23.6B >ADBE

12 Jun 2025, 20:15 UTC

Earnings

Adobe Sees 3Q Rev $5.88B-$5.93B >ADBE

12 Jun 2025, 20:14 UTC

Earnings

Adobe Stock Pops as Earnings Beat Estimates -- Barrons.com

12 Jun 2025, 20:07 UTC

Earnings

Adobe Raises FY25 Rev and EPS Targets

12 Jun 2025, 20:05 UTC

Earnings

Adobe Sees FY Adj EPS $20.50-Adj EPS $20.70 >ADBE

12 Jun 2025, 20:05 UTC

Earnings

Adobe 2Q Digital Experience Revenue $1.46B >ADBE

12 Jun 2025, 20:05 UTC

Earnings

Adobe 2Q Digital Media Revenue $4.35B >ADBE

12 Jun 2025, 20:05 UTC

Earnings

Adobe Sees 3Q EPS $4.00-EPS $4.05 >ADBE

12 Jun 2025, 20:05 UTC

Earnings

Adobe 2Q Net $1.69B >ADBE

12 Jun 2025, 20:05 UTC

Earnings

Adobe 2Q EPS $3.94 >ADBE

12 Jun 2025, 20:05 UTC

Earnings

Adobe 2Q Digital Experience Revenue Up 10% >ADBE

12 Jun 2025, 20:05 UTC

Earnings

Adobe 2Q Rev $5.87B >ADBE

12 Jun 2025, 20:05 UTC

Earnings

Adobe Sees 3Q Adj EPS $5.15-Adj EPS $5.20 >ADBE

12 Jun 2025, 20:05 UTC

Earnings

Adobe Sees FY EPS $16.30-EPS $16.50 >ADBE

12 Jun 2025, 20:05 UTC

Earnings

Adobe 2Q Digital Media Revenue Up 11% >ADBE

12 Jun 2025, 20:05 UTC

Earnings

Adobe 2Q Adj EPS $5.06 >ADBE

Peer Comparison

Price change

Corvus Pharmaceuticals Inc Forecast

Price Target

By TipRanks

206.6% upside

12 Months Forecast

Average 13 USD  206.6%

High 17 USD

Low 11 USD

Based on 4 Wall Street analysts offering 12 month price targets forCorvus Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

4 ratings

4

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

3.165 / 3.5827Support & Resistance

Short Term

Strong Bearish Evidence

Intermediate Term

Bearish Evidence

Long Term

Weak Bearish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.